Micromet to Host Annual Research & Development Day on February 10, 2010

Thursday, February 4, 2010 General News J E 4

BETHESDA, Md., Feb. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that it will host a Research & Development Day for the investment community on Wednesday, February 10, 2010 from 8:00 AM11:00 AM ET at the Yale Club in New York City.  Members of the Company's leadership team will outline near-term development plans for the Company's lead product candidate blinatumomab (MT103) and will provide an update on the Company's earlier stage BiTE® antibodies.

Interested parties may access a live audio webcast of the presentation via the homepage of the Micromet website, or by dialing 866-700-7477 (U.S.) or 617-213-8840 (International), passcode: 23649136.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at

SOURCE Micromet, Inc.



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
New, Targeted Pain Medicine Delivery Systems May R...
Micromet to Present at the 12th Annual BIO CEO & I...